🟢 Moleculin Biotech is trading 8.27% up in pre-market after Zacks’ #2 Buy upgrade; cause unclear

Moleculin Biotech is trading at $0.66 (+8.27%) in pre-market, with no August 25 company announcement, filing, or major catalyst identified.

• Zacks upgraded Moleculin to Rank #2 (Buy) on August 24, citing a 34.2% rise in consensus earnings estimates, but did not confirm it caused the move.
• Slightly positive futures, including a 0.53% Nasdaq gain, may be supporting risk appetite.
• The move remains headline-sensitive and could reflect low-priced biotech volatility.